WASHINGTON, D.C.—Retroperitoneal fibrosis (RPF) is often a challenging diagnosis to make, given a lack of serologic biomarkers and often difficulty in accessing tissue for biopsy, especially in cases confined to the retroperitoneum. The topic of retroperitoneal fibrosis was discussed during the CARE to Test Your Knowledge: Retroperitoneal Fibrosis session at ACR Convergence 2024. John Stone,…
For the 2024 Image Competition, the ACR sought images representing a diverse range of patients with educational or remarkable manifestations of pediatric rheumatic diseases, including autoimmune, inflammatory, infectious and malignant drivers of pediatric rheumatic disease. Here, we showcase the images selected as Best Overall. Cavitary Lung Nodules with Sinus & Skin Disease in Pediatric ANCA-Associated…
It’s dark. It’s cold. And it’s 5 p.m. here in Iowa. If that sounds rather bleak to you, I wouldn’t blame you. But to Stella, my 12-year-old canine companion, it’s a wonderland. She’s half-Shetland sheepdog and half-American Eskimo, so the colder and snowier it is, the more she feels at home. And although I do…
At this ACR Convergence 2024 session, Sonye Danoff, MD, PhD, discussed many factors that need to be considered before referring patients with SARD-ILD for lung transplantation.
Understanding the intersection of diabetes mellitus & rheumatic diseases, including lesser known rheumatic entities of diabetes, such as diabetic cheiroarthropathy, scleredema & diabetic myonecrosis, is crucial for accurate diagnosis.
Adina Greene, BA, Sabrina Dahak, MD, Wesley A. Robertson, MD, Denege Ward-Wright, MD, & Kristen Young, DO, MEd |
Granulomatosis with polyangiitis (GPA) is a small vessel vasculitis associated with anti-neutrophil cytoplasmic antibodies (C-ANCA), specifically proteinase 3 (PR3) ANCA. GPA classically presents with multi-organ involvement. The first description of GPA defined a triad of features: 1) systemic necrotizing angiitis, 2) necrotizing inflammation of the respiratory tract and 3) necrotizing glomerulonephritis.1 Few cases of digital…
Clinicians should not rely on glucocorticoids as a first-line treatment of SARD-ILD in patients with systemic sclerosis, according to a strong recommendation in a new ILD treatment guideline from the ACR and CHEST. The guideline is one of two addressing the screening, monitoring and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs).